Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert

PHASE3CompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

August 2, 2013

Primary Completion Date

March 26, 2018

Study Completion Date

March 26, 2018

Conditions
Non-Infectious Uveitis
Interventions
DRUG

FAI insert

DRUG

Sham injection

Trial Locations (34)

12159

Retina Consultants, Slingerlands

27710

Duke University Eye Center, Durham

29456

Charleston Neuroscience Institute, Ladson

40508

Ophthalmology & Visual Sciences, Lexington

44195

Cleveland Clinic, Cleveland

60611

Northwestern University, Chicago

68198

University of Nebraska Medical Center, Omaha

76012

Texas Retina Associates, Arlington

77030

Retina Consultants of Houston, Houston

78240

Foresight Studies, LLC, San Antonio

80909

Retina Consultants of Southern Colorado, Colorado Springs

90211

Retina Vitreaous Associates, Beverly Hills

90503

Retina Macula Institute, Torrance

95819

Retinal Consultants Medical Group, Inc, Sacramento

97239

OHSU Casey Eye Institute, Portland

02142

Ocular Immunology and Uveitis Foundation, Cambridge

Unknown

Augenarzte am St. Franziskus Hospital, Münster

Universitatsklinikum Tubingen, Tübingen

Bajcsy-Zsilinszky Kórház és Rendelőintézet, Budapest

L. V. Prasad Eye Institute - Hospital, Hyderabad

L.V. Prasad Eye Institute, Pātia

C.H Nagri Municipal Eye Hospital, Ahmedabad

Seth G.S. Medical College & KEM Hospital, Pārel

PBMA'S H.V. Desai Eye Hospital, Hadapsar

King George's Medical University, Lucknow

Hadassah University Hospital Ein Kerem, Jerusalem

Rabin Medical Center, Petah Tikva

Sheba Medical Center, Qiryat Ono

Royal Hospitals Trust, Belfast

Birmingham and Midland Eye Centre, Birmingham

Bradford Royal Infirmary, Bradford

Gloucestershire Royal Hospital, Gloucester

Moorfields Eye Hospital, London

St Thomas Hospital, London

Sponsors
All Listed Sponsors
lead

EyePoint Pharmaceuticals, Inc.

INDUSTRY